List view / Grid view
Dr Danilo Maddalo from Genentech outlines the main benefits of CRISPR within the clinical realm and highlights some of the safety concerns that must be considered before CRISPR products reach patients.
All mice infected with anthrax spores were completely protected after treatment with a pegylated enzyme known as PEG-CapD-CPS334C.
Researchers developed a patient-specific zebrafish model for arrhythmogenic cardiomyopathy (ACM) and tested istaroxime as a potential therapeutic.
The exciting new study demonstrates how the technology could be used to improve animal welfare in scientific research and agriculture.
GlaxoSmithKline (GSK) and the University of Oxford will collaborate to investigate diseases using technologies such as functional genomics and machine learning.
In this article, Drug Target Review's Victoria Rees explores a new method that could enable powerful immune cells to be produced in large quantities to treat a range of cancers.
The study is the first in-depth look at links between COVID-19 severity and gene expression in immune cells and may guide future therapies.
The CRISPR-based therapy called EBT-101 excised HIV proviral DNA from the genomes of different cells and tissues in human cells and mice.
The new findings suggest that inhibiting p53 can reduce CRISPR-associated cancer risks and may lead to developments in precision medicine.
Scientists used a CRISPR-based screen to find that inhibiting MTHFD2 reduces disease severity in inflammatory disease models.
Scientists reveal that higher levels of inflammatory chemicals involved in fat metabolism occur in people with amyotrophic lateral sclerosis.
Rice University scientists have refined specific CRISPR-base editing strategies to avoid errors that occur during gene editing.
The UTX gene mutation was found to lead to an increased cancer risk, presenting a potential drug target for preventative therapies.
The intestine chip was infected with a coronavirus to test a variety of drugs, presenting a new method to investigate COVID-19 treatments.
The study used CRISPR to show that DNA “de-methylation” activity can be targeted to anywhere in the DNA and may be a new therapeutic strategy.
